Tema Oncology ETF

CANC

시가총액 US$1.99억

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.

Tema Oncology ETF receives a Hold rating due to inconsistent returns but it does currently have a high Quant Ranking in the healthcare subclass. CANC offers diversified exposure across market caps and geographies, focusing on firms combating cancer through biotech, pharmaceuticals, diagnostics, and devices. The ETF holds 55 stocks, with top 10 comprising 40% of the portfolio, balancing established giants and innovative small-caps.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role, Mr. Munroe will partner with Tema Founder and CEO Maurits Pot and the firm's leadership team to accelerate the company's next phase of growth. He will oversee branding, marketing, distribution, and product strategy as Tema continues to gain momentum—raising more than $1 billion in net new assets o.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in assets under management (AUM) two years since launch. The CANC ETF invests in leading oncology companies and cancer therapies and is the only pure-play oncology focused ETF in the world, managed by Dr. David Song MD, PhD, CFA.1 Key Highlights of the Tema Oncology ETF (CANC): 1. Rising Oncology Need Canc.

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since launch, achieved with less than $5m of initial seed AUM. Tema also announces the hiring of Devan O'Dowd as Head of Distribution and Ceri Llewelyn as Director of Marketing. Three highlights to note: Institutional Adoption: Tema estimates that over 90% of current AUM originates from Registered Inves.

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.